Elevation Oncology IncHere is the public summary page for Elevation Oncology Inc. Please login to see the complete information for Elevation Oncology Inc including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Elevation Oncology Inc stacks up relative to its peers. |
| Darwin Score | +4 |
| Ticker | ELEV |
| Latest Price | 0.38 USD as of close on 16-Jul-2025 |
| 3 Month price range | 0.28 to 0.39 USD |
| Market Capitalisation | 22.44Mn USD |
| Country | United States of America |
| Region | North America |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Sub-Industry | Biotechnology |
| Description | Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload that is in Phase 1 clinical trial as a monotherapy and in combinations with dostarlimab, a PD-1 inhibitor, and ramucirumab, a VEGFR2 inhibitor, in patients with advanced, unresectable, or metastatic gastric/gastroesophageal junction solid tumors. The company is also developing EO-1022, an ADC containing seribantumab, a fully human immunoglobulin G2 (IgG2) anti-HER3 mAb, and an MMAE payload, with glycan site-specific conjugation for the treatment of patients with HER3-expressing solid tumors, including breast cancer, non-small cell lung cancer, and other solid tumors. It has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021 for the treatment of cancer. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. See More ... |
| Company URL | https://elevationoncology.com |
| See Darwins Full Analysis for Elevation Oncology Inc |
Tell Me About
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Elevation Oncology Inc. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | -9 |
| Sentiment | News and Candle Patterns. | 0 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +2 |
| Flow | Institutional, Fund and Insider buying and selling. | +1 |
| Models | Forecast models. | +10 |
Alerts
There are 4 live alerts for Elevation Oncology Inc. All the alerts are positive.
- Cross Over (Up): 20dma . This alert has occurred 14 times over the last last year. The average forward returns are 0.5% over 5 days, -8.1% over 10 days, -14.2% over 15 days and -16.4% over 20 days. (Positive)
- Divergence: Px Down & OBV Up last 20 days. This alert has occurred 156 times over the last last year. The average forward returns are -1.6% over 5 days, -2.5% over 10 days, -5.6% over 15 days and -9.6% over 20 days. (Positive)
- Cross Over (Up): 5dma . This alert has occurred 31 times over the last last year. The average forward returns are -0.3% over 5 days, -3.4% over 10 days, -7.2% over 15 days and -7.9% over 20 days. (Positive)
- Price crossing up through 5 day SMA. This alert has occurred 31 times over the last last year. The average forward returns are -0.3% over 5 days, -3.4% over 10 days, -7.2% over 15 days and -7.9% over 20 days. (Positive)
Peer Comparison
There are 6 peers of Elevation Oncology Inc.
| Asset Name | Industry Group | Asset Score |
|---|---|---|
| Catalyst Pharmaceuticals Inc (CPRX) | Biotechnology | +7 |
| Revelation Biosciences Inc (REVB) | Biotechnology | -14 |
| Synaptogenix Inc (SNPX) | Biotechnology | +8 |
| TG Therapeutics Inc (TGTX) | Biotechnology | +30 |
| Vaxart Inc (VXRT) | Biotechnology | -22 |
| Windtree Therapeutics Inc (WINT) | Biotechnology | 0 |
Share 
